BRISTOL-MYERS SQUIBB Deliver health and hope in China

Bristol-Myers Squibb is a global biopharmaceutical company with the mission of “developing and delivering innovative medicinesforpatients withserious diseases.” It is a leader in the field of hepatitis, cancer and immuno-oncology.

Bristol-Mercedes-Squibb came to China in 1982. The Sino-American Shanghai Squibb Pharmaceuticals Co Ltd established in the same year is the first Sino-US pharmaceutical company in China. During the 40 years of reform and opening-up, Bristol-Myers Squibb has also left some marks with its efforts to lead innovation and strive forward in China.

The company has made numerous achievements in China: in 1985, it rolled off the first generation of cephalosporin antibiotics; in 1986, it first introduced the angiotensin converting enzyme inhibitors for the treatment of hypertension, benefiting millions of Chinese patients suffering from hypertension and heart failure; in 1995, it launched the first generation of Paclitaxel, ushering in the new era of using chemotherapy to treat tumor in China; in 1999, it launched the classical oral hypoglycemic agents across the globe, benefiting nearly 100 million Chinese patients suffering from Type-II diabetes; in 2006, it launched the oral regimen with high efficacy and low resistance against chronic hepatitis B, bringing hope to Chinese patients with hepatitis B, and getting the approval of pediatric indications in 2017 to help more children with chronic hepatitis B;in 2012, it introduced the world’s second-generation of tyrosine kinase inhibitors to open a new chapter for the targeted therapy of chronic myelognous leukia (CML);in 2017, it launched the first all-oral direct-acting antiviral regimen for hepatitis C in China, making it possible to eliminate hepatitis C. In 2018, Opdivo (nivolumab injection) was launched as the first immuno-oncology (I-O) therapy in China, starting a new era of immuno-oncology treatment.

In 1997, Bristol-Myers Squibb became the first company to work with the government to meet major challenges in public health by funding the Ministry of Health of China with a US$1 million grant for three major projects on health education and training in the 21st century.

Since 2002, the Bristol-Myers Squibb Foundation, with the theme of “delivering hope,” has been focusing on the charity projects on hepatitis. In China, the 27 projects have covered 28 provinces/municipalities/autonomous regions, benefiting more than 8 million patients and providing donations of more thanUS$9.6 million.